OncoCyte Overview
Latest ROE for OncoCyte: 231.74% — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow231.74%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
OncoCyte's return on equity stands at 231.74%. That is above the sector sector average of -5.68%. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.
OncoCyte sits higher the its sector benchmark (-5.68%) with a ROE of 231.74%. That is roughly 4177.7% above the sector mean. Peer context matters because what looks expensive or cheap in absolute terms can be normal for the sector.
A ROE of 231.74% for OncoCyte means each unit of related capital or sales is generating that return rate. Higher is usually better for profitability metrics, but extremely high figures can reflect one-time items or thin equity bases. Review several years of data on this page before extrapolating.
The history chart shows how OncoCyte's ROE evolved across reporting periods, while the comparison chart places 0KCC.L next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.
